Scavenging acrolein with 2-HDP preserves neurovascular integrity in a rat model of diabetic retinal disease
2-HDP protects against retinal NVU dysfunction in diabetic rats by reducing FDP-Lys accumulation, preserving neuroretinal function and preventing microvascular damage, independent of glycaemic control. These results, combined with evidence from human diabetic retinas and molecular dynamics simulations, support 2-HDP's potential as a promising therapeutic agent for DRD, warranting further preclinical and clinical investigation.
Authors
- Timothy J. Lyons (ORCID: https://orcid.org/0000-0003-2106-1622)
- Tim M. Curtis (ORCID: https://orcid.org/0000-0003-1543-2781)
- Alan W. Stitt (ORCID: https://orcid.org/0000-0002-8647-9918)
- Eimear M. Byrne (ORCID: https://orcid.org/0000-0001-5064-3539)
- Paul Canning (ORCID: https://orcid.org/0000-0002-0888-0124)
- Péter Barabás (ORCID: https://orcid.org/0000-0002-8166-3476)
- Sadaf Ashraf (ORCID: https://orcid.org/0000-0001-5592-9122)
- Josy Augustine (ORCID: https://orcid.org/0000-0001-5178-5029)
- Evan P. Troendle (ORCID: https://orcid.org/0000-0003-4825-4088)
- Martin B. Ulmschneider (ORCID: https://orcid.org/0000-0001-8103-0516)
- Alessandra Rollo
- Corey A. McAleese (ORCID: https://orcid.org/0000-0003-2756-4941)
- Thomas Friedel
- Clinton T. Baldwin
Institutions
- Queen's University Belfast (GB)
- Medical University of South Carolina (US)
- Medway School of Pharmacy (GB)
- King's College London (GB)
- BlueCross BlueShield of South Carolina Foundation (US)
Publication Details
- Journal
- Diabetologia
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1007/s00125-025-06515-2
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.12
Funders
- Diabetes UK
- Queen's University Belfast
- Queen's University
- Medical Research Council